Sinomune Pharmaceutical Co., Ltd   Report issue

For profit Phase 3
Founded: Anhui China (2014)

Organization Overview

First Clinical Trial
2019
NCT04456803
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sinomune Pharmaceutical Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

ferric citrate (AURYXIA) (1 trial)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperphosphatemia (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2